Glucagon-like peptide-1 (GLP-1) analogs, which are used in type 2 diabetes mellitus (T2DM), have shown potential anti-inflammatory effects, but their role in thrombotic events in RA is less clear. Here, GLP1R is linked to diabetes mellitus.